Graves’ Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study
- Author:
Yoon Young CHO
1
;
Bongseong KIM
;
Dong Wook SHIN
;
Hye Ryoun JANG
;
Bo-Yeon KIM
;
Chan-Hee JUNG
;
Jae Hyeon KIM
;
Sun Wook KIM
;
Jae Hoon CHUNG
;
Kyungdo HAN
;
Tae Hyuk KIM
Author Information
- Publication Type:Original Article
- From:Endocrinology and Metabolism 2022;37(2):281-289
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Hyperthyroidism is associated with an increased glomerular filtration rate (GFR) in the hyperdynamic state, which is reversible after restoring euthyroidism. However, long-term follow-up of renal dysfunction in patients with hyperthyroidism has not been performed.
Methods:This was a retrospective cohort study using the Korean National Health Insurance database and biannual health checkup data. We included 41,778 Graves’ disease (GD) patients and 41,778 healthy controls, matched by age and sex. The incidences of end-stage renal disease (ESRD) were calculated in GD patients and controls. The cumulative dose and duration of antithyroid drugs (ATDs) were calculated for each patient and categorized into the highest, middle, and lowest tertiles.
Results:Among 41,778 GD patients, 55 ESRD cases occurred during 268,552 person-years of follow-up. Relative to the controls, regardless of smoking, drinking, or comorbidities, including chronic kidney disease, GD patients had a 47% lower risk of developing ESRD (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37 to 0.76). In particular, GD patients with a higher baseline GFR (≥90 mL/min/1.73 m2; HR, 0.33; 95% CI, 0.11 to 0.99), longer treatment duration (>33 months; HR, 0.31; 95% CI, 0.17 to 0.58) or higher cumulative dose (>16,463 mg; HR, 0.29; 95% CI, 0.15 to 0.57) of ATDs had a significantly reduced risk of ESRD.
Conclusion:This was the first epidemiological study on the effect of GD on ESRD, and we demonstrated that GD population had a reduced risk for developing ESRD.
